Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice

Psychopharmacology

Volumn 165, Issue 3, 2003, Pages 245-251

  Kozela, Ewa ^a   Pilc, Andrzej ^a   Popik, Piotr ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Antinociception; Mice; Morphine; Tail flick test; Tolerance

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; GLUTAMATE RECEPTOR; IONOTROPIC RECEPTOR; MEMANTINE; METABOTROPIC RECEPTOR; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CHRONOPHARMACOLOGY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERANCE; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RECEPTOR BLOCKING; TAIL FLICK TEST;

EID: 0037278221     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1287-8     Document Type: Article

References (47)

1. Anwyl R (1999) Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res Brain Res Rev 29:83-120
2. Attucci S, Carla V, Mannaioni G, Moroni F (2001) Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges. Br J Pharmacol 132:799-806
3. Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ (2000) Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20:7871-7879
4. Belozertseva IV, Bespalov AY (1998) Effects of NMDA receptor channel blockers, dizocilpine and memantine, on the development of opiate analgesic tolerance induced by repeated morphine exposures or social defeats in mice. Naunyn Schmiedebergs Arch Pharmacol 358:270-274
5. Bisaga A, Popik P (2000) In search of a new pharmacological treatment of drug addiction: N-methyl-D-aspartate (NMDA) antagonists. Drug Alcohol Depend. 59:1-15
6. Bordi F, Ugolini A (1999) Group I metabotropic glutamate receptors: implications for brain diseases. Prog Neurobiol 59:55-79
7. Chen L, Huang LY (1992) Protein kinase C reduces Mg2+ block of NMDA-receptor channels as a mechanism of modulation. Nature 356:521-523
8. Doherty AJ, Palmer M J, Henley JM, Collingridge GL, Jane DE (1997) (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 36:265-267
9. Fundytus ME, Coderre TJ (1994) Effect of activity at metabotropic, as well as ionotropic (NMDA), glutamate receptors on morphine dependence. Br J Pharmacol 113:1215-1220
10. 2+ release or protein kinase C activation significantly reduces the development of morphine dependence. Eur J Pharmacol 300:173-181
11. Fundytus ME, Ritchie J, Coderre TJ (1997) Attenuation of morphine withdrawal symptoms by subtype- selective metabotropic glutamate receptor antagonists. Br J Pharmacol 120:1015-1020
12. Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, Varney MA, Johnson EC, Hess SD, Rao SP, Sacaan AI, Santori EM, Velicelebi G, Kuhn R (1999) 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38:1493-1503
13. Gubellini P, Saulle E, Centonze D, Bonsi P, Pisani A, Bernardi G, Conquet F, Calabresi P (2001) Selective involvement of mGlu1 receptors in corticostriatal LTD. Neuropharmacology 40:839-846
14. Klodzinska A, Chojnacka-Wojcik E, Palucha A, Branski P, Popik P, Pilc A (1999) Potential anti-anxiety and anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 38:1831-1839
15. Kozela E, Popik P (2002) The effects of NMDA receptor antagonists on acute morphine-antinociception in mice. Amino Acids 23:163-168
16. Kozela E, Danysz W, Popik P (2001) Uncompetitive NMDA receptor antagonists potentiate morphine antinociception recorded from the tail but not from the hind paw in rats. Eur J Pharmacol 423:17-26
17. Mao J (1999) NMDA and opioid receptors: their interactions in antinociception, tolerance and neuroplasticity. Brain Res Brain Res Rev 30:289-304
18. Mao J, Price DD, Phillips LL, Lu J, Mayer DJ (1995) Increases in protein kinase C gamma immunoreactivity in the spinal cord of rats associated with tolerance to the analgesic effects of morphine. Brain Res 677:257-267
19. Mayer DJ, Mao J, Price DD (1995) The development of morphine tolerance and dependence is associated with translocation of protein kinase C. Pain 61:365-374
20. Mestek A, Hurley JH, Bye LS, Campbell AD, Chen Y, Tian M, Liu J, Schulman H, Yu L (1995) The human mu opioid receptor: modulation of functional desensitization by calcium/calmodulin-dependent protein kinase and protein kinase C. J Neurosci 15:2396-2406
21. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt CA, Rhodes GA, Robey RL, Griffey KR, Tizzano JP, Kallman MJ, Helton DR, Schoepp DD (1997) Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY 354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 40:528-537
22. Oleary DM, Movsesyan V, Vicini S, Faden AI (2000) Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Brit J Pharmacol 131:1429-1437
23. Olivar T, Laird JM (1999) Differential effects of N-methyl-D-aspartate receptor blockade on nociceptive somatic and visceral reflexes. Pain 79:67-73
24. Ossowska K, Konieczny J, Wolfarth S, Wieronska J, Pilc A (2001) Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 41:413-420
25. Paronis CA, Holtzman SG (1991) Increased analgesic potency of mu agonists after continuous naloxone infusion in rats. J Pharmacol Exp Ther 259:582-589
26. Parsons CG, Danysz W, Quack G (1999) Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 38:735-767
27. Paul IA, Nowak G, Layer RT, Popik P, Skolnick P (1994) Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 269:95-102
28. Pin JP, Duvoisin R (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34:1-26
29. Pisani A, Gubellini P, Bonsi P, Conquet F, Picconi B, Centonze D, Bernardi G, Calabresi P (2001)Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 106:579-587
30. Popik P, Kozela E, Danysz W (2000a) Clinically available NMDA receptor antagonists memantine and dextromethorphan reverse existing tolerance to the antinociceptive effects of morphine in mice. Naunyn Schmiedebergs Arch Pharmacol 361:425-432
31. Popik P, Kozela E, Pilc A (2000b) Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice. Br J Pharmacol 130:1425-1431
32. Rao AM, Hatcher JF, Dempsey RJ (2000) Neuroprotection by group I metabotropic glutamate receptor antagonists in forebrain ischemia of gerbil. Neurosci Lett 293:1-4
33. Schmidt WJ, Bubser M (1989) Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav 32:621-623
34. Schoepp DD (2001) Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 299:12-20
35. Schoepp DD, Conn PJ (1993) Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol Sci 14:13-20
36. Seif el Nasr M, Peruche B, Rossberg C, Mennel HD, Krieglstein J (1990) Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol 185:19-24
37. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R (1996) Adaptation of the N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 29:23-26
38. Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, Porsolt RD, Gentsch C (2000) Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 295:1267-1275
39. Spooren WP, Gasparini F, Salt TE, Kuhn R (2001) Novel allosteric antagonists shed light on mGlu(5) receptors and CNS disorders. Trends Pharmacol Sci 22:331-337
40. Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R, Pilc A (2001) Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 132:1423-1430
41. Thomas LS, Jane DE, Hams JR, Croucher MJ (2000) Metabotropic glutamate autoreceptors of the mGlu(5) subtype positively modulate neuronal glutamate release in the rat forebrain in vitro. Neuropharmacology 39:1554-1566
42. Thomas LS, Jane DE, Gasparini F, Croucher MJ (2001) Glutamate release inhibiting properties of the novel mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP): complementary in vitro and in vivo evidence. Neuropharmacology 41:523-527
43. Trullas R, Jackson B, Skolnick P (1989) Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnineinsensitive glycine receptors. Pharmacol Biochem Behav 34:313-316
44. Vandergriff J, Rasmussen K (1999) The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropharmacology 38:217-222
45. Walker K, Bowes M, Panesar M, Davis A, Gentry C, Kesingland A, Gasparini F, Spooren W, Stoehr N, Pagano A, Flor PJ, Vranesic I, Lingenhoehl K, Johnson EC, Varney M, Urban L, Kuhn R (2001) Metabotropic glutamate receptor subtype 5 (MGlu5) and nociceptive function I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology 40:1-9
46. Wang ZJ, Arden J, Sadee W (1996) Basal phosphorylation of mu opioid receptor is agonist modulated and Ca2+-dependent. FEBS Lett 387:53-57
47. Welch SP, Bass PP (1995) Modulation of free intracellular calcium levels [(Ca++)i] in brain and spinal cord of morphine tolerant rats and mice. Pharmacol Biochem Behav 51:57-63